MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on December 21, 2007; DOI: 10.1124/mol.107.044586


This Article
Right arrow Full Text (PDF)
Right arrow Related Artcle
Right arrow All Versions of this Article:
mol.107.044586v1
mol.107.044586v2
mol.107.044586v3
mol.107.044586v4
73/3/616    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Henry, L K.
Right arrow Articles by Blakely, R. D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Henry, L K.
Right arrow Articles by Blakely, R. D


Received for publication December 21, 2007.
Revised December 21, 2007.
Accepted for publication December 21, 2007.

Distinctions Between Dopamine Transporter Antagonists Could Be Just Around the Bend

L Keith Henry 1* Randy D Blakely 1

1 Vanderbilt University School of Medicine

* Address correspondence to: E-mail: keith.henry{at}vanderbilt.edu

Abstract

Abuse of psychostimulants such as cocaine and amphetamines has a tremendous social and economic impact. While replacement therapies are offered for addiction to opioids, nicotine and alcohol, there is no approved replacement treatments for psychostimulant addiction. Recent studies on an emerging group of benztropine- and remcazole-based compounds provide hope that replacement therapies for cocaine and amphetamine addiction may come in the near future. A new study now investigates the molecular interaction of the benztropine and remcazole compounds with their target, the dopamine transporter and provides an intriguing explanation as to why use of these compounds, unlike cocaine, do not lead to locomotor stimulation and drug discrimination behaviors in animal models.


Key words: Dopamine, Biogenic Amine, Amphetamines, Cocaine, Drug tolerance/dependence





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics